...
首页> 外文期刊>The Lancet >Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (0pT2mise): a randomised open-label controlled trial
【24h】

Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (0pT2mise): a randomised open-label controlled trial

机译:胰岛素泵治疗与每日多次注射治疗2型糖尿病(0pT2mise)的比较:一项随机开放标签对照试验

获取原文
获取原文并翻译 | 示例
           

摘要

Background Many patients with advanced type 2 diabetes do not meet their glycated haemoglobin targets and randomised controlled studies comparing the efficacy of pump treatment and multiple daily injections for lowering glucose in insulin-treated patients have yielded inconclusive results. We aimed to resolve this uncertainty with a randomised controlled trial (OpT2mise).Methods We did this multicentre, controlled trial at 36 hospitals, tertiary care centres, and referal centres in Canada, Europe, Israel, South Africa, and the USA. Patients with type 2 diabetes who had poor glycaemic control despite multiple daily injections with insulin analogues were enrolled into a 2-month dose-optimisation run-in period. After the run-in period, patients with glycated haemoglobin of 8 ? 0-12 ? 0% (64-108 mmol/mol) were randomly assigned (1:1) by a computer-generated randomisation sequence (block size 2 with probability 0 ? 75 and size 4 with probability 0 ? 25) to pump treatment or to continue with multiple daily injections. Neither patients nor investigators were masked to treatment allocation. The primary endpoint was change in mean glycated haemoglobin between baseline and end of the randomised phase for the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT01182493.
机译:背景许多晚期2型糖尿病患者均未达到糖化血红蛋白的目标,随机对照研究比较了胰岛素治疗患者的泵送治疗和每日多次注射降低血糖的疗效,但结果尚无定论。我们旨在通过随机对照试验(OpT2mise)解决这种不确定性。方法我们在加拿大,欧洲,以色列,南非和美国的36家医院,三级护理中心和转诊中心进行了这项多中心,对照试验。尽管每天多次注射胰岛素类似物但血糖控制仍较差的2型糖尿病患者被纳入为期2个月的剂量优化磨合期。磨合期过后,糖化血红蛋白的患者达到8? 0-12?通过计算机生成的随机序列(块大小为2的概率为0到75,块大小为4的概率为0到25)将0%(64-108 mmol / mol)随机分配(1:1)进行治疗或继续每日多次注射。患者和研究者均未掩盖治疗分配。主要终点是意图治疗人群的基线和随机阶段结束之间的平均糖化血红蛋白变化。该研究已在ClinicalTrials.gov上注册,编号为NCT01182493。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号